Your browser is no longer supported. Please, upgrade your browser.
Settings
IGMS IGM Biosciences, Inc. daily Stock Chart
IGMS [NASD]
IGM Biosciences, Inc.
Index- P/E- EPS (ttm)-2.01 Insider Own2.10% Shs Outstand30.55M Perf Week-9.84%
Market Cap2.25B Forward P/E- EPS next Y-3.26 Insider Trans97.90% Shs Float13.36M Perf Month73.99%
Income-61.50M PEG- EPS next Q-0.69 Inst Own59.00% Short Float11.64% Perf Quarter11.48%
Sales- P/S- EPS this Y-80.00% Inst Trans3.72% Short Ratio11.51 Perf Half Y42.93%
Book/sh6.77 P/B11.19 EPS next Y-17.00% ROA-24.50% Target Price79.00 Perf Year322.89%
Cash/sh6.67 P/C11.36 EPS next 5Y- ROE-26.50% 52W Range16.10 - 89.81 Perf YTD98.48%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-15.67% Beta-
Dividend %- Quick Ratio18.00 Sales past 5Y- Gross Margin- 52W Low370.43% ATR6.05
Employees91 Current Ratio18.00 Sales Q/Q- Oper. Margin- RSI (14)64.74 Volatility9.16% 9.93%
OptionableYes Debt/Eq0.00 EPS Q/Q1.80% Profit Margin- Rel Volume1.03 Prev Close74.15
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume135.12K Price75.74
Recom1.40 SMA2022.33% SMA5034.74% SMA20042.50% Volume138,826 Change2.14%
Jul-17-20Initiated Robert W. Baird Outperform $90
Jul-01-20Initiated H.C. Wainwright Buy $88
May-28-20Initiated SunTrust Buy $86
Apr-22-20Initiated Wedbush Outperform $73
Oct-14-19Initiated Stifel Buy $32
Oct-14-19Initiated Piper Jaffray Overweight $26
Oct-14-19Initiated Jefferies Buy $25
Oct-14-19Initiated Guggenheim Buy $30
Sep-24-20 04:01PM  
Sep-18-20 06:51PM  
Sep-16-20 09:00AM  
Sep-14-20 12:04PM  
Sep-02-20 07:00AM  
Aug-06-20 04:08PM  
Aug-04-20 07:00AM  
Jun-28-20 05:58PM  
Jun-16-20 06:27AM  
May-28-20 07:00AM  
May-12-20 07:00AM  
May-07-20 04:03PM  
12:25PM  
Apr-29-20 04:05PM  
Apr-03-20 07:00AM  
Mar-26-20 04:05PM  
02:30PM  
Mar-19-20 07:00AM  
Mar-04-20 07:00AM  
Feb-06-20 07:00AM  
Jan-07-20 07:00AM  
Dec-22-19 01:29PM  
Nov-12-19 07:00AM  
Nov-07-19 05:04PM  
Nov-01-19 10:24AM  
Oct-02-19 07:00AM  
Sep-20-19 04:05PM  
Sep-18-19 11:03AM  
07:39AM  
Sep-17-19 08:46PM  
04:04PM  
IGM Biosciences, Inc., a biotechnology company, engages in the research and development of Immunoglobulin M (IgM) antibodies for the treatment of cancer. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 1 clinical trials to treat patients with B cell NHL and other B cell malignancies. It is also developing IGM-8444, an IgM antibody targeting Death Receptor 5 proteins; and IGM-7354, is a bispecific IgM antibody delivering interleukin-15 cytokines to PD-L1 expressing cells for use in the treatment of patients with solid and hematologic malignancies. IGM Biosciences, Inc. has a collaboration with Atreca Inc. and BeiGene Ltd. to discover, develop, and manufacture novel IgM and IgA antibodies targeting SARS-CoV-2 for the potential treatment of COVID-19. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chen Daniel ShinYuChief Medical OfficerSep 18Sale77.9160947,447116,518Sep 18 07:14 PM
Chen Daniel ShinYuChief Medical OfficerSep 17Option Exercise1.399501,321117,468Sep 18 07:14 PM
BEHRENS M KATHLEENDirectorSep 10Buy60.7830,0001,823,40893,214Sep 14 08:43 PM
Keyt BruceChief Scientific OfficerSep 10Sale60.001,00060,0002,896Sep 14 08:43 PM
Redmile Group, LLCDirectorSep 09Buy52.5523,2601,222,3353,425,811Sep 09 07:41 PM
Redmile Group, LLCDirectorSep 08Buy49.9147,1132,351,5043,402,551Sep 09 07:41 PM
Chen Daniel ShinYuChief Medical OfficerSep 08Sale50.2060230,220116,518Sep 09 07:17 PM
Redmile Group, LLCDirectorSep 04Buy50.2874,4333,742,1863,355,438Sep 09 07:41 PM
Redmile Group, LLCDirectorSep 03Buy48.6974,2533,615,2083,281,005Sep 03 07:57 PM
Redmile Group, LLCDirectorSep 02Buy46.6820,637963,2673,206,752Sep 03 07:57 PM
Chen Daniel ShinYuChief Medical OfficerSep 01Option Exercise1.399501,321117,468Sep 03 05:52 PM
Redmile Group, LLCDirectorSep 01Buy44.8441,7591,872,3273,186,115Sep 03 07:57 PM
Chen Daniel ShinYuChief Medical OfficerAug 27Sale45.1360527,301116,518Aug 28 06:32 PM
Chen Daniel ShinYuChief Medical OfficerAug 11Option Exercise1.399501,321117,468Aug 13 04:35 PM
Keyt BruceChief Scientific OfficerJun 04Option Exercise3.342,9879,9844,000Jun 08 06:40 PM
BEHRENS M KATHLEENDirectorDec 09Buy24.8720,000497,31610,000Dec 11 07:04 PM